vs
CAMDEN NATIONAL CORP（CAC）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
CAMDEN NATIONAL CORP的季度营收约是Day One Biopharmaceuticals, Inc.的1.6倍（$64.3M vs $39.8M），CAMDEN NATIONAL CORP净利率更高（34.0% vs -49.6%，领先83.6%）
卡姆登国民银行是一家总部位于美国缅因州卡姆登的商业银行，是上市银行控股公司卡姆登国民集团的核心子公司。该行创立于1875年，1984年完成企业重组后成为控股公司直接持有的全资子公司。2025年与诺斯韦金融合并后，合并后机构总资产约为70亿美元。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
CAC vs DAWN — 直观对比
营收规模更大
CAC
是对方的1.6倍
$39.8M
净利率更高
CAC
高出83.6%
-49.6%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.3M | $39.8M |
| 净利润 | $21.9M | $-19.7M |
| 毛利率 | — | — |
| 营业利润率 | — | -60.9% |
| 净利率 | 34.0% | -49.6% |
| 营收同比 | — | -57.6% |
| 净利润同比 | — | -153.3% |
| 每股收益（稀释后） | $1.29 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACDAWN
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | — | ||
| Q3 25 | $65.4M | $39.8M | ||
| Q2 25 | $62.3M | $33.9M | ||
| Q1 25 | $60.1M | $30.8M | ||
| Q4 24 | $47.6M | — | ||
| Q3 24 | $45.0M | $93.8M | ||
| Q2 24 | $42.8M | — |
净利润CACDAWN
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | — | ||
| Q3 25 | $21.2M | $-19.7M | ||
| Q2 25 | $14.1M | $-30.3M | ||
| Q1 25 | $7.3M | $-36.0M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $13.1M | $37.0M | ||
| Q2 24 | $12.0M | — |
营业利润率CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | — | ||
| Q3 25 | 40.5% | -60.9% | ||
| Q2 25 | 28.5% | -103.1% | ||
| Q1 25 | 10.3% | -133.5% | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 35.2% | 31.6% | ||
| Q2 24 | 34.7% | — |
净利率CACDAWN
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | — | ||
| Q3 25 | 32.4% | -49.6% | ||
| Q2 25 | 22.6% | -89.4% | ||
| Q1 25 | 12.2% | -117.0% | ||
| Q4 24 | 30.8% | — | ||
| Q3 24 | 29.1% | 39.5% | ||
| Q2 24 | 28.0% | — |
每股收益（稀释后）CACDAWN
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | — | ||
| Q3 25 | $1.25 | $-0.19 | ||
| Q2 25 | $0.83 | $-0.29 | ||
| Q1 25 | $0.43 | $-0.35 | ||
| Q4 24 | $1.00 | — | ||
| Q3 24 | $0.90 | $0.38 | ||
| Q2 24 | $0.81 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $451.6M |
| 总债务越低越好 | $514.4M | — |
| 股东权益账面价值 | $710.0M | $450.9M |
| 总资产 | $7.0B | $513.8M |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $451.6M | ||
| Q2 25 | — | $453.1M | ||
| Q1 25 | — | $473.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $558.4M | ||
| Q2 24 | — | — |
总债务CACDAWN
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CACDAWN
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | — | ||
| Q3 25 | $676.4M | $450.9M | ||
| Q2 25 | $652.1M | $460.8M | ||
| Q1 25 | $640.1M | $479.5M | ||
| Q4 24 | $531.2M | — | ||
| Q3 24 | $529.9M | $555.5M | ||
| Q2 24 | $508.3M | — |
总资产CACDAWN
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | — | ||
| Q3 25 | $7.0B | $513.8M | ||
| Q2 25 | $6.9B | $519.0M | ||
| Q1 25 | $7.0B | $534.4M | ||
| Q4 24 | $5.8B | — | ||
| Q3 24 | $5.7B | $600.8M | ||
| Q2 24 | $5.7B | — |
负债/权益比CACDAWN
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | — | ||
| Q3 25 | $36.1M | $-5.8M | ||
| Q2 25 | $6.0M | $-24.8M | ||
| Q1 25 | $1.0M | $-59.0M | ||
| Q4 24 | $60.9M | — | ||
| Q3 24 | $-14.5M | $50.8M | ||
| Q2 24 | $14.5M | — |
自由现金流CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | — | ||
| Q3 25 | $35.4M | — | ||
| Q2 25 | $4.5M | $-24.8M | ||
| Q1 25 | $-727.0K | $-59.3M | ||
| Q4 24 | $55.4M | — | ||
| Q3 24 | $-16.2M | $50.0M | ||
| Q2 24 | $13.2M | — |
自由现金流率CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | — | ||
| Q3 25 | 54.1% | — | ||
| Q2 25 | 7.3% | -73.2% | ||
| Q1 25 | -1.2% | -192.8% | ||
| Q4 24 | 116.4% | — | ||
| Q3 24 | -36.0% | 53.4% | ||
| Q2 24 | 30.8% | — |
资本支出强度CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | — | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 2.4% | 0.0% | ||
| Q1 25 | 2.9% | 1.0% | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 3.8% | 0.8% | ||
| Q2 24 | 3.0% | — |
现金转化率CACDAWN
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 4.15× | — | ||
| Q3 24 | -1.11× | 1.37× | ||
| Q2 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
